On the Precipice of a "Rituximab-Like" Era for T-Cell Lymphomas?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37581573.
- Also identified by DOI 10.1158/1078-0432.CCR-23-1571.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To date, mAbs have had limited success in improving outcomes for patients with T-cell lymphomas. Preclinical data suggest that anti-T-cell receptor Vβ-segment mAbs are a novel therapeutic strategy for patients with T-cell lymphomas that avoid several limitations of current therapies. See related article by Lucero et al., p. 4230.